https://www.selleckchem.com/pr....oducts/Temsirolimus.
The study cohort included 1982 patients with median age 74 years, of which 136 (7%) experienced at least one adverse medication event(s). The model included length of stay, hospital re-admission within 12 months, venous or arterial thrombosis and/or embolism, ≥ 8 medications, serum sodium 126 mmol/L, INR 3, anti-psychotic, antiarrhythmic and immunosuppressant medications, and history of medication allergy. Validation gave an AuROC of 0.70 (95% CI 0.65-0.74). Decision curve analysis identified that the AIME may be clinical
Like
Comment
Share
